25.43
1.56%
0.39
시간 외 거래:
25.08
-0.35
-1.38%
전일 마감가:
$25.04
열려 있는:
$25.15
하루 거래량:
756.48K
Relative Volume:
1.17
시가총액:
$1.80B
수익:
$80.89M
순이익/손실:
$-144.73M
주가수익비율:
-8.5623
EPS:
-2.97
순현금흐름:
$-83.87M
1주 성능:
+0.91%
1개월 성능:
+14.55%
6개월 성능:
+98.98%
1년 성능:
+293.65%
누릭스 테라퓨틱스 Stock (NRIX) Company Profile
명칭
Nurix Therapeutics Inc
전화
(415) 660-5320
주소
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
누릭스 테라퓨틱스 Stock (NRIX) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-07-31 | 개시 | Truist | Buy |
2023-06-26 | 재개 | Oppenheimer | Outperform |
2023-03-09 | 개시 | Barclays | Overweight |
2023-02-28 | 개시 | Oppenheimer | Outperform |
2022-10-11 | 개시 | Morgan Stanley | Equal-Weight |
2022-05-31 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
2022-02-10 | 개시 | Wells Fargo | Equal Weight |
2021-12-29 | 개시 | H.C. Wainwright | Buy |
2021-10-14 | 개시 | SVB Leerink | Outperform |
2021-06-04 | 재개 | Robert W. Baird | Outperform |
2021-04-30 | 재개 | Piper Sandler | Overweight |
2021-04-30 | 개시 | RBC Capital Mkts | Outperform |
2021-04-14 | 개시 | Berenberg | Buy |
2020-11-19 | 개시 | Robert W. Baird | Outperform |
2020-08-18 | 개시 | JP Morgan | Overweight |
2020-08-18 | 개시 | Needham | Buy |
2020-08-18 | 개시 | Piper Sandler | Overweight |
2020-08-18 | 개시 | Stifel | Buy |
모두보기
누릭스 테라퓨틱스 주식(NRIX)의 최신 뉴스
Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting - GlobeNewswire
Nurix therapeutics' chief legal officer sells $82,250 in stock - Investing.com
(NRIX) Technical Pivots with Risk Controls - Stock Traders Daily
Nurix therapeutics CFO Hans van Houte sells $86,083 in stock - Investing.com India
Houte Hans Van Sells 3,546 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock - MarketBeat
Nurix therapeutics CFO Hans van Houte sells $86,083 in stock By Investing.com - Investing.com Australia
Nurix therapeutics chief legal officer sells $139,866 in stock By Investing.com - Investing.com South Africa
Nurix therapeutics chief legal officer sells $139,866 in stock - Investing.com India
Insider Sale: CFO Houte Van Sells Shares of Nurix Therapeutics I - GuruFocus.com
Nurix Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth - Simply Wall St
Nurix therapeutics CFO Hans van Houte sells $57,554 in stock By Investing.com - Investing.com South Africa
Nurix therapeutics chief scientific officer sells shares worth $83,536 - Investing.com
Nurix therapeutics chief legal officer sells shares worth over $101k - Investing.com
Nurix therapeutics CFO Hans van Houte sells $57,554 in stock - Investing.com
Nurix therapeutics chief scientific officer sells shares worth $83,536 By Investing.com - Investing.com Australia
Allspring Global Investments Holdings LLC Makes New Investment in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Nurix Therapeutics stock soars to 52-week high of $26.46 By Investing.com - Investing.com Canada
Nurix Therapeutics (NASDAQ:NRIX) Now Covered by UBS Group - Defense World
Nurix Therapeutics (NASDAQ:NRIX) Reaches New 1-Year HighShould You Buy? - MarketBeat
Nurix Therapeutics stock soars to 52-week high of $26.46 - Investing.com India
UBS sees upside for Nurix stock driven by promising NX-5948 data in CLL/SLL - Investing.com India
UBS Group Initiates Coverage on Nurix Therapeutics (NASDAQ:NRIX) - MarketBeat
What is HC Wainwright’s Forecast for NRIX FY2024 Earnings? - Defense World
(NRIX) On The My Stocks Page - Stock Traders Daily
HC Wainwright Has Bullish Estimate for NRIX FY2024 Earnings - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Stock Rating Reaffirmed by Needham & Company LLC - Defense World
Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit - The Manila Times
Nurix Therapeutics (NASDAQ:NRIX) Price Target Raised to $30.00 - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Receives "Buy" Rating from Needham & Company LLC - MarketBeat
Nurix Therapeutics’ NX-5948 shows promise in Waldenstrom’s macroglobulinaemia trial - Clinical Trials Arena
WestHill Financial Advisors Inc. Sells 45,000 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics Presents Positive Results from the - GlobeNewswire
Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom’s Macroglobulinemia - Yahoo Finance
Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia - The Manila Times
Nurix Therapeutics stock soars to 52-week high of $26.31 By Investing.com - Investing.com South Africa
Nurix Therapeutics (NASDAQ:NRIX) Reaches New 52-Week HighHere's What Happened - MarketBeat
Nurix Therapeutics stock soars to 52-week high of $26.31 - Investing.com
The Manufacturers Life Insurance Company Purchases 4,583 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World
Nurix Therapeutics adds pharma veteran Anil Kapur to board - Investing.com
Nurix Therapeutics adds pharma veteran Anil Kapur to board By Investing.com - Investing.com South Africa
Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur - GlobeNewswire
Take off with Nurix Therapeutics Inc (NRIX): Get ready for trading - SETE News
SG Americas Securities LLC Sells 80,254 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Needham & Company LLC Reiterates Buy Rating for Nurix Therapeutics (NASDAQ:NRIX) - Defense World
누릭스 테라퓨틱스 (NRIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
누릭스 테라퓨틱스 주식 (NRIX) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Ring Christine | Chief Legal Officer |
Nov 04 '24 |
Sale |
25.00 |
3,290 |
82,250 |
28,084 |
자본화:
|
볼륨(24시간):